The role of quantitative bias analysis for nonrandomized comparisons in health technology assessment: recommendations from an expert workshop
International Journal of Technology Assessment in Health Care · 2023
DOI: 10.1017/s0266462323002702 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Technology Assessment in Health Care, 2023. Verfasst von Thomas P Leahy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Putnam Associates LLC, Westport, Ireland. Hauptthemen laut MEDLINE: Research Design, Technology Assessment, Biomedical. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
The use of treatment effects derived from nonrandomized studies (NRS) in health technology assessment (HTA) is growing. NRS carry an inherently greater risk of bias than randomized controlled trials (RCTs). Although bias can be mitigated to some extent through appropriate approaches to study design and analysis, concerns around data availability and quality and the absence of randomization mean residual biases typically render the interpretation of NRS challenging. Quantitative bias analysis (QBA) methods are a range of methods that use additional, typically external, data to understand the potential impact that unmeasured confounding and other biases including selection bias and time biases can have on the results (i.e., treatment effects) from an NRS. QBA has the potential to support HTA bodies in using NRS to support decision-making by quantifying the magnitude, direction, and uncertainty of biases. However, there are a number of key aspects of the use of QBA in HTA which have received limited discussion. This paper presents recommendations for the use of QBA in HTA developed using a multi-stakeholder workshop of experts in HTA with a focus on QBA for unmeasured confounding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Putnam Associates LLC, Westport, Ireland.
- AP-HP, Health Economics Research Unit, Department of Public Health, Henri Mondor Hospital, Paris, France.
- Methods, UMRS 1153, French National Institute of Health and Medical Research, Paris, France.
- Faculty of Medicine, Université Paris Est Creteil, Creteil, France.
- Health Technology Assessment (HTA) Unit, Hospital Clinic of Barcelona, Barcelona, Spain.
- Flatiron Health UK, St Albans, UK.
ORCID-Profile: Thomas P Leahy, Isabelle Durand-Zaleski
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Leahy, T. P., Durand-Zaleski, I., Sampietro-Colom, L., Kent, S., Zöllner, Y., Coyle, D., & Casadei, G. (2023). The role of quantitative bias analysis for nonrandomized comparisons in health technology assessment: recommendations from an expert workshop. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462323002702
Vancouver
Leahy TP, Durand-Zaleski I, Sampietro-Colom L, Kent S, Zöllner Y, Coyle D, et al. The role of quantitative bias analysis for nonrandomized comparisons in health technology assessment: recommendations from an expert workshop. International Journal of Technology Assessment in Health Care. 2023. doi:10.1017/s0266462323002702
BibTeX
@article{Leahy2023,
author = {Leahy, Thomas P and Durand-Zaleski, Isabelle and Sampietro-Colom, Laura and Kent, Seamus and Zöllner, York and Coyle, Doug and Casadei, Gianluigi},
title = {The role of quantitative bias analysis for nonrandomized comparisons in health technology assessment: recommendations from an expert workshop},
journal = {International Journal of Technology Assessment in Health Care},
year = {2023},
doi = {10.1017/s0266462323002702}
}
EUVIMED